



(A)

COVID-19 mortality rate per age range




(B)

Covid-19 CFR per age range




Supplementary Figure 1: (A) Average COVID-19 mortality rate per age range (i.e the percentage of COVID-19 deaths per age range among the total number of COVID-19 deaths). (B) Average COVID-19 case fatality rate (CFR) per age range (i.e the percentage of COVID-19 deaths among the COVID-19 positive cases per age range). Data source are reported in Supplementary Tables 1A and B respectively.




Supplementary Figure 2: Co-mention network overview with zoom on single-entity type subnetworks. Labeled subfigures represent samples of the most frequent entities for each respectively colored single-entity type subnetwork from Figure 2.


### Immune Response




### Biology of Viruses




### Diseases and Symptoms




### Infectious Disorders



### Chemical Compounds




Supplementary Figure 3: Co-mention network communities overview. The figure in the center displays a sample of the knowledge graph containing ~1'000 nodes representing the most frequent entities and edges whose NPMI weight  $> 0.2$ . Node sizes are proportional to the weighted degree of nodes, node colors represent different communities detected using the Louvain algorithm and edge thickness is proportional to the NPMI weight of a given entity co-occurrence. Labeled subfigures represent samples of the most frequent entities for each respectively colored community.




Supplementary Figure 4: Spanning-tree constructed from the 1,500-most frequent entities extracted from the 3,000-most relevant papers in the CORD-19v47 database, according to the query “Glucose is a risk factor for COVID-19”. Positions of few key entities are indicated. A high resolution pdf version is available (Figure S4 high res).




**A** Distribution of Comorbidities in COVID -19 deaths by age range




**B**



Supplementary Figure 5: A) Prevalence of comorbidities among COVID-19 related deaths. B) Distribution of death among total case of hospitalization according to gender. Data are from US populations as of April 30, 2020 and detailed in Supplementary Tables 3A and B respectively.



Supplementary Figure 6: Blood glucose in hypertension. (A) Correlation between hypertensive status according to SBP value (SBP=systolic blood pressure in mmHg), and BMI (top) or FPG (bottom). Adapted from Agrawal et al, 2017. (B) Prevalence of impaired fasting glucose (IFG) according to age range and SBP (mmHg). Adapted from Henry et al, 2002. (see Supplementary References)



Supplementary Figure 7: Position of the potential new glycan site on the SARS-CoV-2 P.1 variant. The additional glycan-tree at N20 is colored in red and indicated with arrows on each S monomer of the spike. Position of N165 and N234 glycan-sites are circled on one single monomer.

A

Age range	South Korea	Germany	South Africa	Sweden	Italy	Switzerland	Japan	Ukraine	Global
<b>0-9</b>	0.00	0.04	0.20	0.04	0.01	0.02	0.00	0.00	<b>0.04</b>
<b>10-19</b>	0.00	0.02	0.30	0.01	0.01	0.00	0.00	0.80	<b>0.14</b>
<b>20-29</b>	0.00	0.12	1.30	0.16	0.05	0.00	0.10	0.30	<b>0.25</b>
<b>30-39</b>	0.40	0.24	6.10	0.30	0.22	0.13	0.31	3.60	<b>1.41</b>
<b>40-49</b>	0.80	0.79	12.60	0.73	0.87	0.29	1.12	9.40	<b>3.33</b>
<b>50-59</b>	4.59	3.08	24.40	2.41	3.40	1.58	3.26	19.90	<b>7.83</b>
<b>60-69</b>	11.98	8.47	26.20	6.44	9.76	5.98	9.31	27.70	<b>13.23</b>
<b>70-79</b>	31.74	20.91	17.70	20.94	25.25	20.32	26.29	22.40	<b>23.19</b>
<b>80+</b>	50.50	66.29	11.30	68.93	60.43	71.69	59.61	15.80	<b>50.57</b>
<b>total</b>	<b>100.01</b>	<b>99.96</b>	<b>100.10</b>	<b>99.96</b>	<b>100.00</b>	<b>100.01</b>	<b>100.00</b>	<b>99.90</b>	<b>99.99</b>

B

Age range	South Korea	China	Spain	Italy	Switzerland	Poland	Global
<b>0-9</b>	0.00	0.00	0.01	0.00	0.00	0.00	<b>0.00</b>
<b>10-19</b>	0.00	0.20	0.02	0.00	0.00	0.05	<b>0.05</b>
<b>20-29</b>	0.00	0.20	0.12	0.00	0.00	0.00	<b>0.05</b>
<b>30-39</b>	0.05	0.20	0.32	0.10	0.12	0.15	<b>0.16</b>
<b>40-49</b>	0.10	0.40	1.06	0.20	0.08	0.30	<b>0.36</b>
<b>50-59</b>	0.42	1.30	3.22	0.60	0.65	1.00	<b>1.20</b>
<b>60-69</b>	1.27	3.60	5.00	3.00	3.35	4.50	<b>3.45</b>
<b>70-79</b>	6.68	8.00	14.30	10.20	11.59	11.20	<b>10.33</b>
<b>80+</b>	19.45	14.80	21.10	20.90	28.45	20.05	<b>20.79</b>

**Supplementary Tables 1 (Related to Supplementary Figures 1): A)** COVID-19 mortality rate per age range as of June 2020 in eight different countries. Global rates are plotted in Supplementary Figure 1A. **B)** COVID-19 case fatality rate (CFR) per age range as of June 2020 in six different countries. Global rates are plotted in Supplementary Figure 1B. References are listed in Supplementary References.

A

Rank	Entity	Frequency	Entity type	Rank	Entity	Frequency	Entity type
1	COVID-19	110,145	Symptom / Disease	51	amino acid	14,227	Chemical
2	virus	75,012	Organism	52	pH	14,107	Chemical
3	infectious disorder	73,574	Symptom / Disease	53	gastrointestinal tract	13,510	Organ / System
4	coronavirus	67,945	Organism	54	immunoglobulin	13,198	Protein
5	human	61,816	Organism	55	antibiotic	13,034	Drug
6	viral	52,801	Organism	56	outbreak	12,766	Symptom / Disease
7	SARS-COV-2	49,386	Organism	57	cow	12,656	Organism
8	SARS coronavirus	41,463	Organism	58	transfer	12,625	Biological Process / Pathway
9	blood	33,970	Organ / System	59	tissue	12,542	Organ / System
10	person	33,893	Organism	60	nucleic acids	12,530	Chemical
11	coronaviridae	32,976	Organism	61	ARDS	12,392	Symptom / Disease
12	animal	31,998	Organism	62	brain	12,307	Organ / System
13	lung	31,752	Organ / System	63	cardiovascular system	11,864	Organ / System
14	respiratory system	31,221	Organ / System	64	interferon	11,687	Protein
15	death	31,114	Symptom / Disease	65	skin	11,686	Organ / System
16	host	27,219	Organism	66	renal	11,630	Organ / System
17	bacteria	26,082	Organism	67	human respiratory syncytial virus	11,356	Organism
18	influenza	26,000	Symptom / Disease	68	T-lymphocyte	11,189	Cell Type
19	antibody	24,447	Protein	69	plasma	11,132	Organ / System
20	fever	24,295	Symptom / Disease	70	MERS coronavirus	11,063	Organism
21	vaccine	24,073	Drug	71	disease or disorder	11,035	Symptom / Disease
22	pneumonia	23,998	Symptom / Disease	72	compound	10,907	Chemical
23	viral infection	23,797	Symptom / Disease	73	nucleotide	10,780	Chemical
24	pathogen	23,441	Organism	74	neoplasm	10,750	Symptom / Disease
25	mouse	23,122	Organism	75	enzyme	10,567	Protein
26	heart	22,583	Organ / System	76	cytoplasm	10,364	Cell Compartment
27	DNA replication	21,577	Biological Process / Pathway	77	lower	10,342	Organ / System
28	pulmonary	21,261	Organ / System	78	nuclear	10,305	Cell Compartment
29	serum	20,300	Organ / System	79	antigen	10,263	Drug
30	water	19,746	Chemical	80	immunity	10,236	Biological Process / Pathway
31	survival	18,915	Biological Process / Pathway	81	peptidase	10,156	Protein
32	DNA	16,948	Chemical	82	adenoviridae	10,148	Organism
33	infectious disease pathway	16,882	Biological Process / Pathway	83	adenovirus infection	10,111	Symptom / Disease

34	membrane	16,708	Organ / System	84	hypertension	1,094	Symptom / Disease
35	liver	16,688	Organ / System	85	lymphocyte	10,064	Cell Type
36	inflammation	16,554	Symptom / Disease	86	diarrhea	10,039	Symptom / Disease
37	oral cavity	16,522	Organ / System	87	macrophage	10,028	Cell Type
38	cough	16518	Symptom / Disease	88	proliferation	10,006	Biological Process / Pathway
39	ribonucleic acid	16,397	Chemical	89	ACE2	9,933	Protein
40	cancer	15,767	Symptom / Disease	90	neutrophil	9,920	Cell Type
41	human immunodeficiency virus	15,733	Organism	91	interleukin-6	9,883	Protein
42	organ	15,679	Organ / System	92	nasopharyngeal	9,851	Symptom / Disease
43	kidney	15,600	Organ / System	93	microorganism	9,808	Organism
44	cytokine	15,584	Protein	94	airway	9,703	Organ / System
45	immune response process	15,014	Biological Process / Pathway	95	child	9,650	Organism
46	diabetes mellitus	14,984	Symptom / Disease	96	mammalia	9,643	Organism
47	molecule	14,846	Chemical	97	messenger RNA	9,614	Protein
48	influenza A virus	14,686	Organism	98	eye	9,588	Organ / System
49	SARS	14,372	Symptom / Disease	99	respiratory system disorder	9,528	Symptom / Disease
50	oxygen	14,289	Chemical	100	injury	9,438	Symptom / Disease

B

Rank	Entity	Rank	Entity type
1	water	10	nucleotide
2	DNA	11	viral RNA
3	RNA	12	chemical
4	molecule	13	lipid
5	oxygen	14	reagent
6	amino acid	14	acid
7	pH	16	CO2
8	nucleic acids	17	glucose
9	compound	...	

**Supplementary Tables 2 (Related to Table 1): A)** Ranking of the 100 most frequently mentioned terms in the CORD-19v47 database following COVID-19-related entity types recognition. (i.e. ‘COVID-19’ is mentioned in 110,145 distinct papers). **B)** Ranking of top mentioned terms from the entity type “chemical” in the CORD-19v47 database.

Note that in order to filter out mentions of glucose as a chemical appearing in experimental procedures, we have excluded sections entitled ‘Methods’ and ‘Materials and Methods’ from our analysis.

A

Age range	0-18	19-44	45-54	55-64	65-74	75-84	85+
Total death n	0	241	468	1,181	2,010	2,356	2,087
no comorbidities n (%)	0	97 (40)	126 (27)	225 (19)	261 (13)	283 (12)	292 (14)
Diabetes n (%)	0	36 (15)	56 (12)	106 (9)	141 (7)	141 (6)	84 (4)
Diabetes + Hypertension* n (%)	0	43 (18)	169 (36)	508 (43)	925 (46)	1036 (44)	647 (31)
Hypertension n (%)	0	41 (17)	84 (18)	213 (18)	402 (20)	589 (25)	772 (37)
COPD n (%)	0	17 (7)	5 (1)	35 (3)	60 (3)	71 (3)	63 (3)
Other combinations n (%)	0	7 (3)	28 (6)	94 (8)	221 (11)	236 (10)	229 (11)

B

	Male	Female
Total case (n)	22,566	18,441
Total death (n) (%)	4,937 (22%)	3,406 (18,5%)

**Supplementary Tables 3 (Related to Supplementary Figures 5).** (A) Prevalence of comorbidities among COVID-19 related deaths as plotted in Supplementary Figure 5A. (B) Distribution of death among total cases of hospitalization according to gender as plotted in Supplementary Figure 5B. Data from US populations as of April 30, 2020. Data source: <https://ehrn.org/prevalence-of-comorbidities-in-covid-19-related-hospitalizations-and-deaths/>

**A**

	FPG (mM)		2h PPG (mM)		HbA1c (%)	
	Control	T2DM	Control	T2DM	Control	T2DM
Duraisamy et al, 2010	4.5	9.01	5.32	13.05	5.22	8.97
Bhowmik et al, 2018	4.7	9.5	5.4	13.9	5.3	7.6
Yang et al, 2014	5.26	9.79	5.45	14.53	4.23	8.19
<b>Mean</b>	<b>4.82</b>	<b>9.4</b>	<b>5.4</b>	<b>13.8</b>	<b>4.92</b>	<b>8.3</b>

**B**

	Control		Hypertensive	
	FPG mM	n	FPG mM	n
Mittal, 2014	4.6	50	5.47	70
Tarray et al , 2014	4.92	50	5.31	50
Heianza et al , 2015	5.24	8,486	5.44	1,098
<b>Mean</b>	<b>4.92</b>		<b>5.41</b>	

**Supplementary Tables 4 (Related to Figures 9):** (A) Values of FPG, 2h-PPG and HbA1c in control (n=2,116) versus diabetic patients (n=439) according to values reported in 3 different studies. Mean values are plotted in Figure 9A. (B) Values of FPG in control (n=8,586) versus hypertensive patients (n=1,218) according to values reported in three different studies. Mean values are plotted in Figure 9B. References are listed in Supplementary References.

A

Age	FPG (mM)				Mean
<19	5.2	NA	4.9	4.78	<b>4.96</b>
20-29	5.1	NA	5	4.83	<b>4.98</b>
30-39	5.05	4.44	5.1	4.97	<b>4.89</b>
40-49	5.5	4.61	5.15	5.22	<b>5.12</b>
50-59	5.7	4.78	5.2	5.44	<b>5.28</b>
60-69	5.7	5.06	5.3	5.50	<b>5.39</b>
70-79	5.71	5.39	NA	5.56	<b>5.55</b>
80-89	5.72	5.72	NA	5.64	<b>5.69</b>
>90	5.72	6.06	NA	NA	<b>5.89</b>
	Ko et al, 2006 (n=6,901)	Yashin et al, 2009 (n= 5,128)	Yates and Laing, 2002 (n=191)	Yi et al, 2017 (n>10,000)	

B

Age	FPG in male (mM)		Mean FPG male	FPG in female (mM)		Mean FPG female
<19	NA	4.78	<b>4.78</b>	NA	4.78	<b>4.78</b>
20-29	NA	4.89	<b>4.89</b>	NA	4.78	<b>4.78</b>
30-39	4.44	5.11	<b>4.78</b>	4.39	4.89	<b>4.64</b>
40-49	4.58	5.39	<b>4.99</b>	4.53	5.03	<b>4.78</b>
50-59	4.78	5.56	<b>5.17</b>	4.72	5.22	<b>4.97</b>
60-69	5.17	5.56	<b>5.36</b>	5.03	5.42	<b>5.22</b>
70-79	5.67	5.56	<b>5.61</b>	5.42	5.56	<b>5.49</b>
80-89	5.78	5.61	<b>5.69</b>	5.78	5.67	<b>5.72</b>
>90	6.11	NA	<b>6.11</b>	6.33	NA	<b>6.33</b>
	Yashin et al, 2009 (n= 2,336)	Yi et al, 2017 (n>10,000)		Yashin et al, 2009 (n=2,873)	Yi et al, 2017 (n>10,000)	

C

Age	2h PPG (mM)				Mean
20-29	6.11	7.22	7.28	NA	<b>6.87</b>
30-39	6.22	7.44	7.61	5.9	<b>6.79</b>
40-49	6.78	7.67	8.00	6.2	<b>7.16</b>
50-59	7.22	7.22	8.39	6.5	<b>7.33</b>
60-69	7.78	8.44	8.72	7.1	<b>8.01</b>
70-79	7.78	8.39	9.61	8	<b>8.44</b>
80-89	NA	9.22	10.10	8.4	<b>9.24</b>
	Chia et al, 2018 (n=2,777)	Elahi et al, 1982 (n=186)	Elahi et al, 2000 (n=NA)	Shikomata et al, 1991 (n=742)	

**Supplementary Tables 5 (Related to Figures 8):** **(A)** Values of FPG in function of age range according to data reported in 4 different studies. Mean values are plotted in Figure 8A. **(B)** Values of FPG in function of age range and gender according to data reported in 2 different studies. Mean values are plotted in Figure 8B. **(C)** Values of 2h PPG after an OGTT test in function of age range according to values reported in 4 different studies. Mean values are plotted in Figure 8C. The number of participants (n) in each study is reported. In some cases, absolute values are not reported and then directly extracted from raw plots. All references are available in the manuscript or in Supplementary References.

## **Supplementary References**

**References Supplementary Table 1A:** (1–10)

**References Supplementary Table 1B:** (5, 11, 12)

**References Supplementary Tables 4:** (13–18)

**References Supplementary Tables 5:** (19–25)

**References Knowledge Graphs Methods:** (26–31)

**References BioExplorer Methods:** (32–38)

**References Computational Modeling Methods:** (39–44)

1. La répartition par âge des décès liés au coronavirus ressemble à une mortalité classique -

Libération, [https://www.liberation.fr/direct/element/la-repartition-par-age-des-deces-lies-au-coronavirus-ressemble-a-une-mortalite-classique\\_112144/](https://www.liberation.fr/direct/element/la-repartition-par-age-des-deces-lies-au-coronavirus-ressemble-a-une-mortalite-classique_112144/)

2. • Sweden: coronavirus deaths by age | Statista,

<https://www.statista.com/statistics/1107913/number-of-coronavirus-deaths-in-sweden-by-age-groups/>

3. • Spain: coronavirus mortality rate by age 2020 | Statista,

<https://www.statista.com/statistics/1105596/covid-19-mortality-rate-by-age-group-in-spain-march/>

4. • South Korea: coronavirus death cases by age 2020 | Statista,

<https://www.statista.com/statistics/1105080/south-korea-coronavirus-deaths-by-age/>

5. • Poland: Coronavirus (COVID-19) fatalities by age 2020 | Statista,

<https://www.statista.com/statistics/1110890/poland-coronavirus-covid-19-fatalities-by-age/>

6. • Netherlands: coronavirus deaths by age 2021 | Statista,

<https://www.statista.com/statistics/1109459/coronavirus-death-casualties-by-age-in-netherlands/>

7. • Italy: coronavirus death rate by age | Statista,

<https://www.statista.com/statistics/1106372/coronavirus-death-rate-by-age-group-italy/>

8. • COVID-19 deaths by age and gender Ukraine 2020 | Statista,

<https://www.statista.com/statistics/1109638/covid-19-deaths-by-age-and-gender-ukraine/>

9. • Coronavirus (COVID-19) deaths in Switzerland by age group 2021 | Statista,

<https://www.statista.com/statistics/1110092/coronavirus-covid-19-deaths-age-group-switzerland/>

10. • Coronavirus (COVID-19) deaths by gender and age Germany 2021 | Statista,

<https://www.statista.com/statistics/1105512/coronavirus-covid-19-deaths-by-gender-germany/>

11. What we know about the victims of the coronavirus pandemic in Switzerland - The Local,

<https://www.thelocal.ch/20200409/what-we-know-about-the-victims-of-the-coronavirus-pandemic-in-switzerland>

12. M Roser; H Ritchie; E Ortiz-Ospina; J Hasell. Coronavirus Pandemic (COVID-19),

<https://ourworldindata.org/coronavirus>

13. Y Yang; L Gao; D-J Wang; F-R Li; Y-H Yan; X-Y Wang; X Liao; Q Huang; H Zhang;

Q-R Chen; Q Wang; Y Weng; M-H Song. Comparison of 25-hydroxy vitamin D3,

adiponectin and apolipoprotein A5 levels in subjects with different glucose tolerance and their correlation with blood lipid. *Biomed Res* 25, 5 (2014)

14. R Tarray; S Saleem; D Afrose; I Yousuf; A Gulnar; B Laway; S Verma. Role of insulin resistance in essential hypertension. *Cardiovascular Endocrinology & Metabolism* 3, 129–133 (2014)

15. Y Mittal. Fasting Blood Glucose Level in Patients Suffering From Hypertension. *Asian Journal of Biomedical and Pharmaceutical Sciences* 4, 4 (2014)

16. Y Heianza; Y Arase; S Kodama; SD Hsieh; H Tsuji; K Saito; S Hara; H Sone. Fasting glucose and HbA1c levels as risk factors for the development of hypertension in Japanese

individuals: Toranomon hospital health management center study 16 (TOPICS 16). *J Hum Hypertens* 29, 254–259 (2015)

17. P Duraisamy; S Elango; VP Vishwanandha; R Balamurugan. Prevalence of Mitochondrial tRNA Gene Mutations and Their Association with Specific Clinical Phenotypes in Patients with Type 2 Diabetes Mellitus of Coimbatore. *Genetic Testing and Molecular Biomarkers* 14, 49–55 (2010)

18. B Bhowmik; T Siddiquee; A Mujumder; T Ahmed; H Mahtab; AKA Khan; A Hussain; G Holmboe-Ottesen; TK Omsland. Diabetes Risk Score for Identifying Cardiometabolic Risk Factors in Adult Bangladeshi Population. *Journal of Diabetology* 9, 8 (2018)

19. S-W Yi; S Park; Y-H Lee; H-J Park; B Balkau; J-J Yi. Association between fasting glucose and all-cause mortality according to sex and age: a prospective cohort study. *Sci Rep* 7, 8194 (2017)

20. AP Yates; I Laing. Age-related increase in haemoglobin A1c and fasting plasma glucose is accompanied by a decrease in β cell function without change in insulin sensitivity: evidence from a cross-sectional study of hospital personnel. *Diabetic Medicine* 19, 254–258 (2002)

21. AI Yashin; SV Ukrantseva; KG Arbeev; I Akushevich; LS Arbeeva; AM Kulminski. Maintaining physiological state for exceptional survival: What is the normal level of blood glucose and does it change with age? *Mech Ageing Dev* 130, 611–618 (2009)

22. GT Ko; HP Wai; JS Tang. Effects of Age on Plasma Glucose Levels in Non-diabetic Hong Kong Chinese. *Croat Med J* 47, 709–713 (2006)

23. D Elahi; D Muller. Carbohydrate metabolism in the elderly. *Eur J Clin Nutr* 54, S112–S120 (2000)

24. D Elahi; DC Muller; SP Tzankoff; R Andres; JD Tobin. Effect of Age and Obesity on Fasting Levels of Glucose, Insulin, Glucagon, and Growth Hormone in Man. *Journal of Gerontology* 37, 385–391 (1982)

25. H Shimokata; DC Muller; JL Fleg; J Sorkin; AW Ziembra; R Andres. Age as independent determinant of glucose tolerance. *Diabetes* 40, 44–51 (1991)
26. JY Yen. Finding the K Shortest Loopless Paths in a Network. *Management Science* 17, 712–716 (1971)
27. M Neumann; D King; I Beltagy; W Ammar. ScispaCy: Fast and Robust Models for Biomedical Natural Language Processing. *Proceedings of the 18th BioNLP Workshop and Shared Task* 319–327 (2019)
28. J Lee; W Yoon; S Kim; D Kim; S Kim; CH So; J Kang. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. *Bioinformatics* btz682 (2019)
29. G Fragoso; S de Coronado; M Haber; F Hartel; L Wright. Overview and utilization of the NCI thesaurus. *Comp Funct Genomics* 5, 648–654 (2004)
30. L Danon; J Duch; A Diaz-Guilera; A Arenas. Comparing community structure identification. *J Stat Mech* 2005, P09008–P09008 (2005)
31. G Bouma. Normalized (Pointwise) Mutual Information in Collocation Extraction. *Proceedings of the Biennial GSCL Conference 2009* (2009)
32. R Yan; Y Zhang; Y Li; L Xia; Y Guo; Q Zhou. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 367, 1444–1448 (2020)
33. A Watson; MJS Phipps; HW Clark; C-K Skylaris; J Madsen. Surfactant Proteins A and D: Trimerized Innate Immunity Proteins with an Affinity for Viral Fusion Proteins. *J Innate Immun* 11, 13–28 (2019)
34. Y Watanabe; JD Allen; D Wrapp; JS McLellan; M Crispin. Site-specific analysis of the SARS-CoV-2 glycan shield. *Microbiology* (2020)

35. A Shajahan; S Archer-Hartmann; NT Supekar; AS Gleinich; C Heiss; P Azadi. Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. *Biochemistry* (2020)
36. BW Neuman; BD Adair; C Yoshioka; JD Quispe; G Orca; P Kuhn; RA Milligan; M Yeager; MJ Buchmeier. Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy. *JVI* 80, 7918–7928 (2006)
37. I-N Hsieh; X De Luna; MR White; KL Hartshorn. The Role and Molecular Mechanism of Action of Surfactant Protein D in Innate Host Defense Against Influenza A Virus. *Front Immunol* 9, 1368 (2018)
38. YM Bar-On; A Flamholz; R Phillips; R Milo. SARS-CoV-2 (COVID-19) by the numbers. *eLife* 9, e57309 (2020)
39. FP Schwarz; KD Puri; RG Bhat; A Surolia. Thermodynamics of monosaccharide binding to concanavalin A, pea (*Pisum sativum*) lectin, and lentil (*Lens culinaris*) lectin. *Journal of Biological Chemistry* 268, 7668–7677 (1993)
40. A Kussrow; E Kaltgrad; ML Wolfenden; MJ Cloninger; MG Finn; DJ Bornhop. Measurement of Monovalent and Polyvalent Carbohydrate–Lectin Binding by Back-Scattering Interferometry. *Anal Chem* 81, 4889–4897 (2009)
41. R Jolivet; JS Coggan; I Allaman; PJ Magistretti. Multi-timescale Modeling of Activity-Dependent Metabolic Coupling in the Neuron-Glia-Vasculature Ensemble. *PLoS Comput Biol* 11, e1004036 (2015)
42. MQ Gaunsbaek; KJ Rasmussen; MF Beers; EN Atochina-Vasserman; S Hansen. Lung surfactant protein D (SP-D) response and regulation during acute and chronic lung injury. *Lung* 191, 295–303 (2013)
43. Y Contreras-Baeza; PY Sandoval; R Alarcón; A Galaz; F Cortés-Molina; K Alegría; F Baeza-Lehnert; R Arce-Molina; A Guequén; CA Flores; A San Martín; LF Barros.

Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments. *Journal of Biological Chemistry* 294, 20135–20147 (2019)

44. S Anand. Size distribution of virus laden droplets from expiratory ejecta of infected subjects. *Scientific Reports* 9 (2020)